Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03357731 · ClinicalTrials.gov registry record · Phase 2
A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function
A Phase 2 study of Heart Failure and Cardiac Failure, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 18
- Study locations
NCT03357731: Completed Phase 2 study of Heart Failure and Cardiac Failure, sponsored by Bristol-Myers Squibb.
NCT03357731 is a Phase 2 study of Heart Failure and Cardiac Failure that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 49 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 18 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03357731, a Phase 2 study of Heart Failure and Cardiac Failure, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.
Primary Outcome
The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG HNO Donor
- DRUG Nitroglycerin (NTG)
Study Locations (18)
Other
- Local Institution - Groiningen
- Local Institution - Edinburgh
- Local Institution - Glasgow
- Local Institution - Glasgow
- Local Institution - Glasgow
- Local Institution - Harrow
- Local Institution - London
- Local Institution - London
- Local Institution - London
California
- Orange County Research Center - Tustin
Illinois
- Northwestern Medicine - Chicago
Indiana
- Indiana University School of Medicine-Indianapolis - Indianapolis
Massachusetts
- Brigham and Womens Hospital - Boston
North Carolina
- Duke Advanced Heart and Lung Failure Clinic - Durham
Virginia
- Inova Heart and Vascular Institute - Falls Church
Aichi-ken
- Local Institution - Nagoya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2019-05-10 |
| Phase | Phase 2 |
What the finished NCT03357731 record still lists
NCT03357731 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03357731 lists 18 locations in 10 states (Other, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT03357731 about?
NCT03357731 is a clinical study titled "A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function". The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.
What is the current status of trial NCT03357731?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2017-11-30. Estimated completion is 2019-05-10.
What conditions does trial NCT03357731 study?
This clinical trial studies the following conditions: Heart Failure, Cardiac Failure, Reduced Ventricular Ejection Fraction.
What interventions are being tested in trial NCT03357731?
The interventions under investigation include: Placebo (OTHER), HNO Donor (DRUG), Nitroglycerin (NTG) (DRUG).
Who is sponsoring clinical trial NCT03357731?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03357731 being conducted?
This trial has 18 study locations across California, Illinois, Indiana, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03357731's enrollment target sits among peer trials
49 293rd of 397 higher than 105 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI